FTC gives Lilly a go-ahead for Novartis animal health unit deal; Novartis snags EU approval for glaucoma treatment;

@FiercePharma: Pfizer turns the sex talk toward 50-ish women with menopause awareness push. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Cubist has its Zerbaxa OK. Can Merck make the launch justify its $9.5B buyout? Article | Follow @CarlyHFierce

> The Federal Trade Commission cleared Eli Lilly's ($LLY) $5.4 billion deal for Novartis' ($NVS) animal health unit as long as Lilly sells its Sentinel line of products for treating heartworm in dogs. Story

> Novartis scored EU approval for its Travatan eye drop treatment for adult patients with glaucoma. More (sub. req.)

> Novartis and Vanda Pharmaceuticals settled a licensing dispute over schizophrenia drug Fanapt. Story

> Johnson & Johnson ($JNJ) is planning to roll out a daily disposable multifocal lens product next year. More

> GlaxoSmithKline ($GSK) and partner Ligand Pharmaceuticals ($LGND) submitted an application for a new indication of Promacta for pediatric patients 6 years old and older with chronic immune (idiopathic) thrombocytopenia (ITP). Release

> South Africa's Cipla Medpro won a 2 billion rand ($173 million) contract to supply antiretroviral drugs for the next three years to the government's anti-AIDS program. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Asante files for $45M IPO to market cheap, easy insulin pump. More | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ interview comments: NIH launches crowdsourcing challenge to commercialize its neurological medical devices. Report | Follow @VarunSaxena2

@EmilyWFierce: Check out @FierceBiotech's latest special report for this year's biotech winners and losers. More | Follow @EmilyWFierce

> Study: Devices for obstructive sleep apnea could improve symptoms of depression. Article

> Trio of med techs file IPOs to raise a total of up to almost $140M. Story

Biotech News

@FierceBiotech: New special report: Best and worst 2014 biotech performers on Wall Street. Feature | Follow @FierceBiotech

@JohnCFierce: Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact. Article | Follow @JohnCFierce

@DamianFierce: $ABBV's Viekira pitch includes this boomer-focused quiz thing on Facebook, featuring rotary phones and candy paper. More | Follow @DamianFierce

> J&J inks an antibody discovery deal with Sevion. Item

> Vanda settles its squabble with Novartis and pockets $25M for its trouble. Story

> Medivation buys into PD-1, picking up where Teva left off. Article

> Ariad flips Iclusig's Asian rights to Otsuka for $77.5M-plus. Report

Biotech Research News

> Northwestern team claims they have found the right way to ID Alzheimer's early on. Report

> New research points to a key driver--and new drug target--behind hepatitis infections. More

> Brown U dean points to a possible suspect driving metastasis. Article

> Stem cell investigator resigns in wake of controversy. Item

> J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration. Story

Pharma Manufacturing News

> Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax. Item

> Bayer picks Cardinal Health to manufacture Xofigo in U.S. News

> Fujifilm becomes part of U.S. pandemic defense with deal for Kalon Biotherapeutics. More

> India warns Egyptian companies claiming to have Sovaldi for sale. Article

> Fresenius closes out recall started two years ago. Story

And Finally… The Indian government is slashing its 2014/2015 healthcare budget by nearly 20% due to fiscal strains. Story

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.